Announced
Completed
Financials
Tags
biotechnology company
Single Bidder
Completed
Acquisition
Cyprus
Majority
Biotechnology
Cross Border
Private
Friendly
Synopsis
Medicover, a specialised provider of diagnostic and healthcare services, completed the acquisition of a 68.3% stake in NIPD Genetics, a European biotechnology company, for $51m. “NIPD’s proprietary technology platform together with their experienced expert team and Medicover Genetics state-of-the art diagnostics will take us one step closer to become an international market leader in genetic diagnostics”, Fredrik Rågmark, Medicover CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.